General Information of Drug (ID: DMERWUC)

Drug Name
Organon Drug Info
Synonyms
Allylestrenol; Allyloestrenol; Allyloestrenolum; Gestanin; Gestanol; Gestanon; Gestanyn; Orageston; Perselin; Turinal; Allilestrenolo [DCIT]; Alilestrenol [INN-Spanish]; Allylestrenol [INN:JAN]; Allylestrenol(jan); Allylestrenolum [INN-Latin]; Gestanon-r; Perselin (TN); Allylestrenol (JAN/INN); (17beta)-17-prop-2-en-1-ylestr-4-en-17-ol; (8R,9S,10R,13S,14S,17R)-13-methyl-17-prop-2-enyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol; 17-(2-Propenyl)estr-4-en-17-ol; 17-Hydroxy-17-alpha-allyl-4-estrene; 17-alpha-Allyl-17-beta-hydroxy-4-estrene; 17-alpha-Allyl-17-beta-hydroxy-delta(sup 4)-estren; 17-alpha-Allyl-3-deoxy-19-nortestosterone; 17-alpha-Allyl-4-oestrene-17-beta-ol; 17-alpha-Allylestr-4-en-17-beta-ol; 17-alpha-Allylhydroxy-19-nor-4-androstene; 17.alpha.-Allyl-17-.beta.-hydroxy-.delta.(sup 4)-estren; 17.alpha.-Allyl-17.beta.-hydroxy-4-estrene; 17.alpha.-Allyl-3-deoxy-19-nortestosterone; 17.alpha.-Allyl-4-destrene-17.beta.-ol; 17.alpha.-Allyl-4-estren-17.beta.-ol; 17.alpha.-Allyl-4-oestrene-17.beta.-ol; 17.alpha.-Allylestr-4-en-17.beta.-ol; 17.alpha.-Allylestrenol; 17alpha-Allyl-17beta-hydroxy-4-estrene; 17alpha-Allyl-19-nor-delta-4-androstene-17beta-ol; 17alpha-Allyl-3-deoxy-19-nortestosterone; 17alpha-Allyl-4-destrene-17beta-ol; 17alpha-Allyl-4-estren-17beta-ol; 17alpha-Allyl-4-oestrene-17beta-ol; 17alpha-Allylestr-4-en-17beta-ol; 17alpha-Allylestrenol; 21-Methylene-19-nor-17-alpha-preg-4-en-17-ol; 3-Deoxy-17-alpha-allyl-19-nortestosterone
Indication
Disease Entry ICD 11 Status REF
Schizophrenia 6A20 Preclinical [1]
Cross-matching ID
PubChem CID
235905
ChEBI ID
CHEBI:31189
CAS Number
CAS 432-60-0
TTD Drug ID
DMERWUC
INTEDE Drug ID
DR0068

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Clinical Trial Drug(s)
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
R1678 DM4K9WH Schizophrenia 6A20 Phase 3 [5]
BI 425809 DMH3XDR Schizophrenia 6A20 Phase 3 [6]
Iclepertin DM83JCK Schizophrenia 6A20 Phase 3 [7]
AMG 747 DMWPGB8 Schizophrenia 6A20 Phase 2 [8]
ORG-25935 DMWN2EC Psychotic disorder 6A20-6A25 Phase 2 [9]
PF-3463275 DMO02LU Schizophrenia 6A20 Phase 2 [8]
GlyT1 PET radiotracers DMCKZUT Schizophrenia 6A20 Phase 1 [10]
ALX-5407 DMLJWPN Schizophrenia 6A20 Phase 1 [11]
JNJ-17305600 DMMI4XR Schizophrenia 6A20 Phase 1 [12]
DCCCyB DMQ8ACY Schizophrenia 6A20 Phase 1 [13]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [14]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [15]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [16]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [17]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [18]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [19]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [20]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [21]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [15]
Verapamil DMA7PEW Angina pectoris BA40 Approved [22]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Androgen receptor (AR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [23]
Nilutamide DMFN07X Prostate cancer 2C82.0 Approved [23]
Hydroxyflutamide DMGIZF5 Prostate cancer 2C82.0 Approved [23]
Enzalutamide DMGL19D Prostate cancer 2C82.0 Approved [24]
Bicalutamide DMZMSPF Prostate cancer 2C82.0 Approved [25]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [26]
Drospirenone DM1A9W3 Acne vulgaris ED80 Approved [27]
Nitrendipine DM21C09 Hypertension BA00-BA04 Approved [28]
Selenium DM25CGV N. A. N. A. Approved [29]
Spironolactone DM2AQ5N Chronic heart failure BD1Z Approved [30]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glycine transporter GlyT-1 (SLC6A9) TTHJTF7 SC6A9_HUMAN Blocker [2]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) Main DME DE4LYSA CP3A4_HUMAN Substrate [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Androgen receptor (AR) OTUBKAZZ ANDR_HUMAN Gene/Protein Processing [4]

References

1 Receptor binding of allylestrenol, a progestagen of the 19-nortestosterone series without androgenic properties. J Steroid Biochem. 1985 Aug;23(2):165-8.
2 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
3 Identification of the human P450 enzymes involved in the in vitro metabolism of the synthetic steroidal hormones Org 4060 and Org 30659. Xenobiotica. 2002 Feb;32(2):109-18.
4 Effect of anti-estrogens on the androgen receptor activity and cell proliferation in prostate cancer cells. Urol Res. 2004 Dec;32(6):406-10. doi: 10.1007/s00240-004-0424-8. Epub 2004 Aug 14.
5 Clinical pipeline report, company report or official report of Roche (2009).
6 Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. Lancet Psychiatry. 2021 Mar;8(3):191-201.
7 Effects of the Glycine Transporter-1 Inhibitor Iclepertin (BI 425809) on Sensory Processing, Neural Network Function, and Cognition in Animal Models Related to Schizophrenia. J Pharmacol Exp Ther. 2022 Aug;382(2):223-232.
8 Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nat Rev Drug Discov. 2013 Nov;12(11):866-85.
9 The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial. J Clin Psychopharmacol. 2014 Apr;34(2):190-8.
10 Glycine Transport Inhibitors for the Treatment of Schizophrenia. Open Med Chem J. 2010; 4: 10-19.
11 ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter. Mol Pharmacol. 2001 Dec;60(6):1414-20.
12 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 935).
13 Identification of an Orally Bioavailable, Potent, and Selective Inhibitor of GlyT1. ACS Med Chem Lett. 2010 October 14; 1(7): 350-354.
14 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
15 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
16 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
17 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
18 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
19 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
20 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
21 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
22 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
23 TBECH, 1,2-dibromo-4-(1,2 dibromoethyl) cyclohexane, alters androgen receptor regulation in response to mutations associated with prostate cancer. Toxicol Appl Pharmacol. 2016 Sep 15;307:91-101. doi: 10.1016/j.taap.2016.07.018. Epub 2016 Jul 27.
24 Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Res. 2015 Jul 13;43(12):5880-97. doi: 10.1093/nar/gkv262. Epub 2015 Apr 23.
25 Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells. Prostate. 2005 Nov 1;65(3):268-75. doi: 10.1002/pros.20282.
26 Effects of the environmental estrogens bisphenol A, o,p'-DDT, p-tert-octylphenol and coumestrol on apoptosis induction, cell proliferation and the expression of estrogen sensitive molecular parameters in the human breast cancer cell line MCF-7. J Steroid Biochem Mol Biol. 2002 Jan;80(1):61-70. doi: 10.1016/s0960-0760(01)00173-x.
27 Identifying environmental chemicals as agonists of the androgen receptor by using a quantitative high-throughput screening platform. Toxicology. 2017 Jun 15;385:48-58. doi: 10.1016/j.tox.2017.05.001. Epub 2017 May 4.
28 Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci Rep. 2014 Sep 26;4:6437. doi: 10.1038/srep06437.
29 Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res. 2004 Jan 1;64(1):19-22. doi: 10.1158/0008-5472.can-03-2789.
30 Comparison of the Hershberger assay and androgen receptor binding assay of twelve chemicals. Toxicology. 2004 Feb 15;195(2-3):177-86. doi: 10.1016/j.tox.2003.09.012.